The published research, “Proficiency Testing of Epidermal Growth Factor Receptor Mutations Detection in Saliva Using Spectrum Saliva Collector (SDNA-1000) and Preservative Solution Detected by Electric Field-Induced Release and Measurement,” Feng Li et al, is an unprecedented feat in modern medicine.
Many advances in targeted treatments for lung cancer are based on the evaluation of three EGFR gene mutations. Current methods for diagnosis and monitoring include invasive tissue biopsies, which create clinical obstacles for ongoing mutation analysis and cancer treatment. The less invasive liquid biopsy options using free-floating cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) in solid tumor cancers have quickly become an important part of the screening, diagnosis and monitoring process for cancer patients.
